Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS

Company Overview - Nordicus Partners Corporation is a financial consulting company focused on supporting Nordic and U.S. life sciences companies in entering the U.S. market [1] - The company is publicly traded and acts as a business accelerator and holding company for Nordic life sciences firms [4] - In 2024, Nordicus acquired 100% of two Danish preclinical-stage biotech companies: Orocidin A/S and Bio-Convert A/S [4] New Company Formation - Nordicus announced the formation of a new company, NoviThera Aps, aimed at researching and developing a novel monoclonal antibody therapy for psoriasis [1] - Mr. Allan Wehnert has been appointed as the CEO of NoviThera [3] Psoriasis Treatment Development - NoviThera is developing a unique monoclonal antibody treatment that may potentially cure psoriasis or prevent its occurrence [2] - Psoriasis is characterized as an immune-mediated inflammatory disease leading to keratinocyte hyperproliferation and inflammation [2] - The treatment development will utilize a human rat model to express endogenous pathological peptides and will be tested in relevant animal disease models [3]